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2 human ER isoforms exist, the ‘classic’ ERa (Green et al, 1986)
and the more recently identified ERb (Kuiper et al, 1996;
Mosselman et al, 1997). Immunohistochemical analysis of ERa in
breast cancer is now routine practice and plays a major role in the
selection of adjuvant therapy in patients with this disease (Harvey
et al, 1999). Pilot work at the mRNA level suggests a role for ERb
in tamoxifen resistance (Speirs et al, 1999a). However, few studies
have investigated protein expression in archival material. This is
fundamental because there is no guarantee that mRNA will be
translated into functional protein. Recently, immunohistochemical
detection of ERb was reported in frozen sections of normal (Speirs
et al, 2000) and malignant breast (Jarvinen et al, 2000). However,
for ERb to be of clinical use it is essential to identify a suitable
antibody for its detection in formalin-fixed, paraffin-embedded
tumours, since the majority of clinical samples are processed in
this way. Therefore, we have optimized an antigen retrieval histo-
chemical technique using a suitable antibody, capable of detecting
ERb protein in archival human breast carcinomas. 
MATERIALS AND METHODS 
With ethical approval, 65 breast carcinomas (35 infiltrating ductal,
15 lobular, 9 tubular/cribriform, 4 mucinous, 1 DCIS, 1 medullary)
and 8 normal breast tissues were randomly selected. None of the
patients had been treated pre-operatively with endocrine therapy.
Detection of ERb by immunohistochemistry (IHC) was performed
using a monoclonal antibody (ERb-14C8, Abcam, Cambridge,
UK). The antibody was affinity-purified and raised by immunizing
mice with a recombinant protein encoding 1–153 amino acids of
human ERb sequence. According to the manufacturers 14C8 did
not cross react with hERa. This was further confirmed by incu-
bating 14C8 and anti-ERa (1D5, Dako, UK) with an ERb blocking
peptide (sc-6820P; Autogen Bioclear, UK). Appropriate positive
controls (normal human breast) and negative (omission of primary
antibody, incubation with blocking peptide) were also included. 
5 mm sections were mounted on Superfrost slides (BDH, Poole,
UK), microwaved in 0.01 M citrate buffer, pH 6.0, for 27 min at
480 W then incubated overnight with 5 mg ml–1 primary antibody
at 4˚C. Next, sections were incubated with biotinylated secondary
antibody followed by streptavidin/peroxidase complex (Vectastain
Quick Kit) at room temperature and visualized with 3,3¢-diamino-
benzidine (all Vector, Peterborough, UK). Sections were counter-
stained with haematoxylin, dehydrated and coverslipped. Slides
were observed under a Nikon light microscope and images
captured using Lucia software (version 4.51). A simple scoring
system was used involving assessment of both staining intensity
and percentage positivity, generating a numerical score of 0–8. A
score of >2 was classified as positive (Allred et al, 1998). Staining
was scored independently by two authors (GPS, PJC). Statistical
analysis was performed using Fisher’s exact test. 
RESULTS 
Consistent, strong ERb staining was detected specifically in cell
nuclei of both epithelial and myoepithelial cells from normal breast
ducts and lobules, both in breast reduction specimens and normal
tissue adjacent to tumours (Figure 1A, B). 74% of carcinomas
(48/65) exhibited specific nuclear staining for ERb (Figure 1C,D,E).
Light cytoplasmic staining was visualized in some tumours, scored
as ERb negative if seen alone, whilst occasional weak to moderate
staining was seen in surrounding stromal cells. Specific staining was
abolished where primary antibody was substituted with blocking
serum or pre-absorbed with an ERb blocking peptide (Figure 1F).
No effect of this peptide was seen with primary antibody directed
against ERa (data not shown). Results obtained between different
test runs were consistently reproducible. 
Compared with infiltrating ductal carcinomas, invasive lobular,
tubular/cribriform and mucinous tumours showed significantly
increased ERb positivity (P = 0.02, Table 1), illustrating the differ-
ences in biological characteristics between distinct tumour types.
However, when the results were correlated with clinico-
pathological features, ERb was significantly associated with ERa,
PR and well-differentiated tumours (Table 1). 
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Figure 1 (A) Immunohistochemical detection of ERb protein in cell nuclei of breast ducts. Note occasional positivity in stromal cells (arrow). (B) ERb
expression in the nuclei of both epithelial (red arrows) and myoepithelial cells (black arrows) of normal mammary glands. (C) Invasive ductal carcinoma showing
specific nuclear staining for ERb. (D) Strong ERb immunoreactivity localized in cell nuclei of an invasive lobular carcinoma. (E) Invasive tubular/cribriform
tumour expressing ERb protein. (F) Serial section of (A) showing abolition of specific staining following pre-absorption of primary antibody with an ERb blocking




Our results unequivocally demonstrate that ERb can be routinely
detected, in archival, formalin-fixed, paraffin-embedded breast
tumours using the 14C8 monoclonal antibody. This may have
profound clinical implications, as it will now allow detailed
receptor analysis in the routine diagnostic setting. 
ERb was co-expressed with ERa in 74% of tumours and
showed a strong association with PR and well-differentiated
tumours. This is in concordance with Jarvinen (2000), but refutes
the observations of Dotzlaw et al (1999). However, the latter study
was conducted at the mRNA level, highlighting that caution
should be observed when extrapolating mRNA results to those of
protein. 
Many ERb antibodies have become commercially available
over the last year. Despite this, there is a paucity of studies investi-
gating this protein in breast tumours. Taylor and Al-Azzawi (2000)
reported ERb in a range of formalin-fixed normal human material,
including breast. They used 2 polyclonal antibodies raised against
the N- and C-termini of hERb (06–629, Upstate Biotechnology;
PAI-310, Affinity Bioreagents, USA respectively). In addition,
Jarvinen et al (2000) reported successful detection of ERb in
frozen tumours, using a different polyclonal antibody (PAI-313,
Affinity Bioreagents, USA), but interestingly their attempts with
paraffin material were unsuccessful. Frozen sections are
performed infrequently in routine practice, so there is a need for a
suitable antibody and a reliable technique for use in paraffin
sections. To our knowledge, this is one of the first studies reporting
ERb in paraffin-embedded human breast carcinomas. The avail-
ability of 14C8 should help resolve conflicting reports proposing
ERb as a good (Jarvinen et al, 2000) or poor (Dotzlaw et al, 1999;
Speirs et al, 1999a,b) prognostic factor in breast cancer. 
Presence of ERb in breast tumours may help explain the diffe-
rential tissue- or gene-specific effects, which have been reported
with oestrogens/antioestrogens (Paech et al, 1997). The relative
expression of ER subtypes seems to alter during tumorigenesis in
terms of mRNA (Leygue et al, 1998); if this is borne out at protein
level, it could have relevance with respect to novel selective
ER modulators, currently being developed against specific ER
phenotypes. When these become available, they could offer the
possibility of individually tailored therapy based on the particular
receptor profiles of breast carcinomas. 
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Table 1 Association of ERb with clinico-pathological features in 65 breast carcinomas 
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